“PHA’s research program has yielded an explosion of understanding about PH that was not known before.” John Newman, MD, Vanderbilt University Medical Center

Twenty years ago there were no pulmonary hypertension treatments available. Through focused research there are now fourteen PH-specific treatments with more in development. But we know that your ultimate wish is for a cure, and that is why PHA will continue to support the work of researchers until the day when no one suffers from PH.

PHA’s Research Program

PHA’s Research Program has committed approximately $8 million for PH research by leveraging partnerships with the National Heart, Lung, and Blood Institute (NHLBI) and the American Thoracic Society (ATS). We have supported 70 promising researchers through four independently reviewed, cutting-edge research programs.

PH Treatments: What’s on the Horizon

View a recording on PHA Classroom of a May 2015 webinar in which Dr. Ioana Preston of Tufts Medical Center covers the current treatments available for PH as well as new treatments in the pipeline.

Current Treatments

PHA’s Scientific Leadership Council’s Education Committee has put together comprehensive fact sheets on all the treatments available for pulmonary hypertension.

Clinical Trials

Stay informed about ongoing clinical research pertaining to evaluation and treatment of pulmonary hypertension through PHA’s PH clinical trial listings, and be sure to post information about the PH clinical trial work you are doing.

Research Corner in Pathlight

Every issue of Pathlight, PHA’s quarterly magazine, features a Research Corner with information about some of the latest research.


The Redefining Pulmonary Hypertension through Pulmonary Vascular Disease Phenomics (PVDOMICS) program is a network of seven clinical sites and a data coordinating center—funded by the National Heart, Lung, and Blood Institute of the National Institutes of Health with additional support from the Pulmonary Hypertension Association—that will perform comprehensive, deep phenotyping across the current World Health Organization (WHO)-classified pulmonary hypertension (PH) Groups 1 through 5.